Patent · US Active

Anti-angiogenic therapy

US9085617B2 · kind B2 · utility

0Cited by

11References

22Claims

0Family size

Assignees

ThromboGenics NV · BE
VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW · BE
Life Sciences Research Partners VZW · BE

Inventors

Jean-Marie Stassen · Bad Buchau, DE
Peter Carmeliet · Blanden, BE
Desire Collen · Winksele, BE

Key dates

Filing date	Feb 3, 2014
Grant date	Jul 21, 2015
Priority date	—
Expiry date	Feb 3, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/24
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.